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Transforming growth factor (TGF)-b represents a
prototype of multifunctional cytokine. Its broad
activities include, among others, context-speci®c
inhibition or stimulation of cell proliferation, control
of extracellular matrix (ECM) synthesis and degrad-
ation, control of mesenchymal±epithelial interactions
during embryogenesis, mediation of cell and tissue
responses to injury, control of carcinogenesis, and
modulation of immune functions. Regulation of pro-
duction and turnover of ECM components is essen-
tial for tissue homeostasis and function. TGF-b
exerts its effects on cell proliferation, differentiation,
and migration in part through its capacity to modu-
late the deposition of ECM components. Speci®cally,
TGF-b isoforms have the ability to induce the
expression of ECM proteins in mesenchymal cells,
and to stimulate the production of protease inhibi-
tors that prevent enzymatic breakdown of the ECM.
Deregulation of these functions is associated with
abnormal connective tissue deposition, as observed,
for example, during scarring or ®brotic processes. In
this review we discuss the current understanding of
the signaling mechanisms used by TGF-b to elicit its
effects on target genes, focusing primarily on Smad
proteins and their role in the transcriptional regula-
tion of ECM gene expression. Other signaling
mechanisms, such as the MAP/SAP kinase or Ras
pathways, although potentially important for trans-
mission of some of the TGF-b signals, will not be
described. Transforming growth factor-b (TGF-b)
plays a critical role in the regulation of extracellular
matrix gene expression. Its overexpression is believed
to contribute to the development of tissue ®brosis.
The recent identi®cation of Smad proteins, TGF-b
receptor kinase substrates that translocate into the
cell nucleus to act as transcription factors, has
increased our understanding of the molecular
mechanisms underlying TGF-b action. This review
focuses primarily on the mechanisms underlying
Smad modulation of gene expression and how they
relate to wound healing. Potential implications for
the development of therapeutic approaches against
tissue ®brosis are discussed. Key words: IGF-b/gene
expression regulation/intracellular signaling/Smad proteins/
target genes. J Invest Dermatol 118:211±215, 2002
THE TGF-b SUPER-FAMILY, STRUCTURE AND
ACTIVATION
The TGF-b super-family of growth factors includes the various
forms of TGF-b, bone morphogenic proteins (BMP), nodals,
activins, the anti-Mullerian hormone, and many other structurally
related factors found in vertebrates, insects, and nematodes
(MassagueÂ, 1998). There are three mammalian isoforms of TGF-
b (TGF-b1±3), structurally nearly identical, with a knot motif
composed of six cysteine residues joined together by three
intrachain disul®de bonds that stabilize b-sheet bands. One free
cysteine forms an interchain disul®de bond with an identical
monomeric chain to generate the mature TGF-b dimer.
TGF-b are secreted as latent precursor molecules (LTGF-b)
requiring activation into a mature form for receptor binding and
subsequent activation of signal transduction pathways. The LTGF-
b molecules consist of 390±414 amino acids. They contain an
amino-terminal hydrophobic signal peptide region, the latency-
associated peptide (LAP) region, of 249 residues, and the C-
terminal, potentially bioactive region that contains 112 amino acids
per monomer. LTGF-b is usually secreted as a large latent complex
covalently bound via the LAP region to LTGF-b-binding protein
(LTBP; Roberts, 1998) or as a small latent complex without LTBP.
The LAP confers latency to the complex, whereas LTBP serves to
bind TGF-b to the ECM and to enable its proteolytic activation
(Nunes et al, 1997).
Activation of TGF-b is a complex process involving conforma-
tional changes of LTGF-b, induced by either cleavage of the LAP
by various proteases such as plasmin, thrombin, plasma transglu-
taminase, or endoglycosylases, or by physical interactions of the
LAP with other proteins, such as thrombospondin-1, leading to the
release of bioactive, mature, TGF-b (Roberts, 1998).
TGF-b/Smad SIGNAL TRANSDUCTION MACHINERY
TGF-b receptors Upon activation, TGF-b superfamily
members initiate their cellular action by binding to serine/
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threonine kinase receptors. The TGF-b receptor family consists of
two structurally similar subfamilies, type I and type II receptors,
with small cysteine-rich extracellular regions and intracellular
portions consisting mainly of their kinase domains. Type I receptors
have a region rich in glycine and serine residues (GS domain)
preceding the receptor kinase domain (Huse et al, 1999). To exert
their signal, type II and type I receptors act in sequence: TGF-b
®rst binds to the type II receptor (TbRII), which occurs in the cell
membrane in an oligomeric form with intrinsic kinase activity;
TGF-b type I receptor (TbRI) is then recruited and
phosphorylated in its GS domain by TbRII, leading to activation
of its kinase activity and subsequent intracellular signaling
(MassagueÂ, 1998; Piek et al, 1999). Betaglycan, a transmembrane
proteoglycan also known as TbRIII (Lopez-Casillas et al, 1991),
allows high-af®nity binding of TGF-b to TbRII but does not itself
transduce signal (Rodriguez et al, 1995; Brown et al, 1999).
Smad proteins Following ligand activation, signaling from
TbRI to the nucleus occurs predominantly by phosphorylation
of cytoplasmic mediators belonging to the Smad family (Piek et al,
1999; MassagueÂ and Chen, 2000; MassagueÂ and Wotton, 2000).
Type I receptors speci®cally recognize and phosphorylate the
ligand-speci®c receptor-activated Smad (R-Smad, Fig 1).
The latter are recruited to activated TbRI by a membrane bound
cytoplasmic protein called SARA (Smad Anchor for Receptor
Activation; Tsukazaki et al, 1998). R-Smad include Smad1, Smad5,
and Smad8 downstream of the BMP, and Smad2 and Smad3
downstream of TGF-b and activin. They all consist of two
conserved Mad-homology (MH) domains that form globular
structures separated by a linker region (Shi et al, 1997). The N-
terminal MH1 domain has DNA-binding activity, whereas the C-
terminal MH2 domain has protein-binding properties.
Phosphorylation of R-Smad by type I receptors occurs principally
on two serine residues within a conserved ±SS(M/V)S±motif at
their C-terminus (MassagueÂ and Chen, 2000; MassagueÂ and
Wotton, 2000).
Upon phosphorylation by TbRI, R-Smad form heteromeric
complexes with co-Smad, such as Smad4. Co-Smad act as a
convergent node in the Smad pathways downstream of the TGF-b
superfamily receptors, complexing R-Smad, regardless of the TGF-
b ligand speci®city of the latter. R-Smad/Smad4 complexes are
then translocated into the nucleus by a mechanism involving the
cytoplasmic protein importin (Xiao et al, 2000; Kurisaki et al,
2001). They may then function as transcription factors, binding
DNA either directly or in association with other DNA binding
proteins (Piek et al, 1999; MassagueÂ and Chen, 2000; MassagueÂ and
Wotton, 2000). Maximal af®nity of recombinant Smad3 and
Smad4 to DNA is observed with the 5 bp sequence, CAGAC (Shi
et al, 1998; Zawel et al, 1998). Smad2, on the other hand, does not
bind DNA directly, requiring a nuclear DNA-binding protein of
the Fast family to bind DNA, in association with Smad4, and
activate transcription in response to TGF-b and activin (Chen et al,
1997; LabbeÂ et al, 1998; Liu et al, 1999).
A third group of Smad proteins, the inhibitory Smad (I-Smad),
such as Smad6 or Smad7, prevent R-Smad phosphorylation and
subsequent nuclear translocation of R-Smad/Smad4 heterocom-
plexes (Imamura et al, 1997; Nakao et al, 1997).
Following target gene transcription, Smad complexes are
released from the chromatin and undergo ubiquitination, followed
by proteasomal degradation (Zhu et al, 1999).
A summary of the various steps of TGF-b signaling through the
Smad cascade is provided in Fig 2.
TRANSCRIPTIONAL CROSS-TALKS
Several cross-signaling mechanisms have been described that
implicate Smad proteins. For example, Smad3 interacts with the
vitamin D receptor to mediate the effect of TGF-b on vitamin D3-
induced transcription (Yanagisawa et al, 1999). Smad3 also interacts
with TFE3 and Sp1 to activate transcription from the PAI-1 and
p21cip promoters, respectively (Hua et al, 1998; Moustakas and
Kardassis, 1998). Smad/AP±1 interactions have also been reported,
which may lead to either additive (Zhang et al, 1998; Liberati et al,
1999; Verrecchia et al, 2001c) or antagonistic (Verrecchia et al,
2000; Verrecchia et al, 2001c) activities on gene transactivation.
Figure 2. Schematic representation of the Smad signaling
cascade downstream of the TGF-b receptors. Initiation of signaling
occurs when TGF-b binds to the serine/threonine kinase known as
TbRII. Ligand-bound TbRII complexes with and phosphorylates the
transducer receptor, TbRI, which becomes activated. Activated TbRI
then recruits and phosphorylates R-Smad, leading to the association of
the latter with a co-Smad, such as Smad4, and translocation of the
formed heterocomplex into the nucleus where it acts as a transcriptional
regulator of target genes.
Figure 1. Structural domains of an R-Smad. R-Smad consist of
two conserved globular domains known as MH1 (Mad homology 1) and
MH2 domains, linked by a linker region. In the basal state, R-Smad
remain in an inactive conformation through an auto-inhibitory MH1/
MH2 interaction. Phosphorylation of the C-terminal SSXS motif by
activated TbRI results in R-Smad activation, heteromerization with
Smad4, and subsequent translocation into the cell nucleus. The Smad3
domain in MH1 recognizes the DNA sequence CAGAC; the MH2
domain is involved in protein/protein interactions with co-Smad,
transcriptional coactivators and corepressors.
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The outcome is dependent on the structure of target promoters, as
not only the presence of AP-1- and/or Smad-speci®c cis-elements,
but also their respective positions, may in¯uence the transcriptional
response (Liberati et al, 1999; Verrecchia et al, 2001c). For example,
in a promoter context exhibiting Smad-speci®c boxes distant from
functional AP-1 sites, such as in the PAI-1 and c-jun promoters,
transcriptional cooperation between Smad and Jun has been
observed, without formation of Smad/Jun heterocomplexes on
DNA (Liberati et al, 1999; Verrecchia et al, 2001c). In the context
of the COL7A1 promoter that possesses an AP-1 site located within
a bipartite Smad-speci®c TGF-b-response element, inhibition of
Smad-driven transactivation by Jun members was observed, again
without formation of Smad/Jun heterocomplexes on DNA. In the
latter case, Jun was shown to act as a direct repressor of Smad
function, binding to and blocking transcriptional activation
domains intrinsic to Smad3, and preventing its binding to DNA
(Verrecchia et al, 2001c).
Another possibility for Smad to interfere with other transcription
factors occurs through direct interactions with transcriptional
coactivators such as the Ski-interacting protein (SKIP) or CBP/
p300. The latter proteins modify transcription either by altering
chromatin structure so that the underlying DNA sequences are
exposed to the transcriptional apparatus (Workman and Kingston,
1998), or by directly recruiting the RNA polymerase II
holoenzyme to the promoter (Snowden and Perkins, 1998).
Smad±CBP/p300 interaction is required for transcriptional acti-
vation of several TGF-b-dependent promoters (Feng et al, 1998;
Janknecht et al, 1998; Nishihara et al, 1998; Pouponnot et al, 1998;
Shen et al, 1998). SKIP, a nuclear hormone receptor coactivator,
enhances TGF-b-dependent transactivation by interacting with
Smad2 and Smad3 proteins (Leong et al, 2001).
In addition, several nuclear proteins, including the viral
oncoprotein E1A (Nishihara et al, 1999), the proto-oncogenes c-
Ski and SnoN (Akiyoshi et al, 1999; Stroschein et al, 1999), TGIF
(Wotton et al, 1999), Snip-1 (Kim et al, 2000), SIP1 (Verschueren et
al, 1999), and c-Jun (Verrecchia et al, 2000) compete for R-Smad/
Smad4 binding to CBP or p300, thereby interfering with
Smad-dependent gene expression.
TGF-b/Smad MODULATION OF ECM GENE
EXPRESSION
Despite extensive research directed toward the elucidation of the
role played by Smad proteins downstream of TGF-b, very few
direct Smad target genes have been characterized. Indeed, it was
shown that transactivation of the ®bronectin gene downstream of
TGF-b is a JNK-speci®c, Smad-independent, mechanism (Hocevar
et al, 1999), suggesting that pathways that alternate to the Smad
cascade also play an important part in the modulation of ECM gene
expression by TGF-b.
Recently, using a combined cDNA microarray/promoter
transactivation approach, we have identi®ed several new Smad
gene targets among which are COL1A1, COL3A1, COL5A2,
COL6A1, COL6A3, and TIMP-1. Most notably, these data
indicate that the Smad signaling pathway is crucial for simultaneous
activation of several ®brillar collagen genes by TGF-b. About 60
other ECM-related genes were also identi®ed as immediate-early
genes targets downstream of TGF-b (Verrecchia et al, 2001a).
Our group identi®ed the ®rst described genuine Smad binding
sequence (SBS) within the human COL7A1 promoter
(Vindevoghel et al, 1998a, b). Speci®cally, TGF-b upregulation
of COL7A1 gene expression is mediated by rapid and transient
binding of a Smad-containing complex to the region ±496/±444 of
the COL7A1 promoter, a bipartite element consisting of a CAGA
tandem repeat in its 5¢ end, and a Medea-like (Drosophila Smad4
homolog) binding site in 3¢, both framing a potential AP-1 binding
site whose integrity is not necessary for either Smad-driven
transactivation or Smad/DNA complex formation (Verrecchia
et al, 2001c). A few other ECM-related genes whose expression is
modulated by TGF-b have also been identi®ed as potential Smad
targets, and CAGA-like elements have been identi®ed within their
promoter regions, that bind Smad complexes. These genes include
PAI-1, COL1A2, and the b5 integrin gene (INTB5) (Chen et al,
1998; Dennler et al, 1998; Lai et al, 2000). In these three cases,
TGF-b-induced promoter activation may also involve functional
interactions between Smad and Sp1, a mechanism that has also been
shown to be critical for activation of p21/WAF1/CIP1 (Pardali
et al, 2000) and p15/Ink4B (Feng et al, 2000) by TGF-b in the
control of cell proliferation.
Regarding COL1A2, initial observations demonstrated that a
135 bp region of the COL1A2 promoter within 330 bp of the
transcription start site confers responsiveness to TGF-b (Inagaki
et al, 1994). The minimal TGF-b-response element was further
re®ned to the region between nucleotides ±271 and ±235 (Chung
et al, 1996). The latter contains potential overlapping cis-element
for Smad, AP-1, and NF-kB (Chung et al, 1996; Chen et al, 1998;
Kouba et al, 1999). Cooperation between Smad3 and Sp1, the latter
binding upstream elements, to transactivate the COL1A2 promoter
has been described (Zhang et al, 2000; Inagaki et al, 2001). The role
of this cooperation in mediating the TGF-b effect is unclear, as
elimination of the corresponding Sp1 sites upstream of the Smad-
speci®c CAGACA motif does not prevent TGF-b-driven pro-
moter transactivation (Chung et al, 1996). Also, it has been shown
that Smad±p300/CBP interactions are a key event in TGF-b-
driven collagen gene transactivation (Ghosh et al, 2000), and that
interferon-g-driven antagonistic activity against TGF-b effect is
integrated at the level of p300/CBP, the latter being sequestered by
interferon-induced Stat1a (Ghosh et al, 2001).
Besides playing a part in the regulation of the expression of ECM
components, Smad have recently been identi®ed as capable of
mediating the inhibitory activity of TGF-b on interstitial
collagenase (matrix metalloproteinase-1) gene activation by pro-
in¯ammatory cytokines (Yuan and Varga, 2001). In that study, the
authors demonstrate that Smad3 and Smad4, but not Smad1 or
Smad2, overexpression block IL-1-driven transactivation of the
matrix metalloproteinase-1 promoter, both by and via p300
sequestration.
Smad SIGNALING IN WOUND HEALING AND FIBROSIS
Numerous studies have documented the ability of exogenous TGF-
b to improve wound healing (Roberts and Sporn, 1993). Recent
work involving inactivation of the Smad3 gene in mice has allowed
to explore speci®cally the contribution of the Smad pathway to
tissue repair (Ashcroft et al, 1999). In contrast to predictions made
on the basis of the ability of exogenous TGF-b to improve wound
healing, Smad3-null (Smad3ex8/ex8) mice paradoxically show
accelerated cutaneous wound healing compared with wild-type
mice, characterized by an increased rate of re-epithelialization and
signi®cantly reduced local in®ltration of monocytes. Smad3ex8/ex8
keratinocytes show altered patterns of growth and migration, and
Smad3ex8/ex8 monocytes exhibit a selectively blunted chemotactic
response to TGF-b. From these data, it may therefore be concluded
that Smad3 may mediate in vivo signaling pathways that are
inhibitory to wound healing. These data suggest that ``natural''
wound healing may involve suppression of the Smad3 level, and
that complete loss of this signaling intermediate further accelerates
the wound healing process. In the same study, it was shown that
reduced deposition of ECM in Smad3±/± mice could be reversed
with the addition of exogenous TGF-b1, which implies that ECM
gene regulation by TGF-b in ®broblasts in vivo may also occur via
Smad-independent pathways. Also, this report indicates that
disruption of the Smad3 pathway in vivo, coupled with exogenous
TGF-b signaling through intact alternate pathways, may be of
therapeutic bene®t in accelerating all aspects of impaired wound
healing.
Type I collagen and ECM accumulation is one of the hallmarks
of ®brotic conditions. For example, affected skin areas from patients
with systemic sclerosis exhibit abnormal accumulation of various
ECM components, predominantly type I and type III collagens, but
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also types V and VII, as well as various proteoglycans.
Accumulation of ECM proteins in ®brotic conditions is accom-
panied by elevated mRNA steady-state levels of ®brillar collagens
(KaÈhaÈri et al, 1984; Ohta and Uitto, 1987). It is generally accepted
that transcriptional activation of ECM-related genes, and in
particular that of collagen genes, is a critical event underlying the
progressive nature of tissue ®brosis, as is observed in cutaneous
lesions from systemic sclerosis or keloid scars (reviewed in Jimenez
and Saitta, 1999; Uitto and Kouba, 2000). An essential factor
contributing to the metabolic modulation of ECM genes expres-
sion is TGF-b, although other factors such as connective tissue
growth factor, whose expression is controlled by TGF-b in a
Smad-dependent manner (Holmes et al, 2001; Leask et al, 2001),
which may contribute to some of the TGF-b effects on
extracellular matrix gene expression and subsequent development
of tissue ®brosis.
INTERFERING WITH FIBROTIC PROCESSES
It is reasonable to hypothesize that a better understanding of the
mechanisms of TGF-b-mediated upregulation of ECM gene
expression in ®brotic conditions will provide promising and
novel approaches to the therapy of these incurable diseases. In
this context, it should be noted that the transcription factor Sp1 is
able to interact physically with Smad proteins, leading for example
to the activation of the p21, p15, and COL1A2 genes in response to
TGF-b (Moustakas and Kardassis, 1998; Feng et al, 2000; Inagaki et
al, 2001). Sp1 is also important for the basal expression of various
collagens, as well as for the expression of TGF-b itself (Geiser et al,
1993). Altering the function of Sp1 may therefore represent an
interesting alternative to interfere with the pro-®brotic activities of
TGF-b. In this context, we have recently demonstrated that Sp1
gene targeting in ®broblasts broadly inhibits ECM gene expression,
as measured using differential hybridization of cDNA microarrays,
as well as various promoter transactivation assays (Verrecchia et al,
2001b). In addition, using a transgenic mouse model carrying a
COL1A2 promoter/luciferase reporter transgene, we have shown
that decoy Sp1-binding oligonucleotides inhibit COL1A2 pro-
moter activity in vivo. Such an approach, once optimized, may
represent an interesting therapeutic alternative toward the treat-
ment of ®brotic disorders.
Altering the Smad pathway may also be achieved at the level of
transcriptional coactivators, such as p300. For example, it has been
shown that RelA, cJun, and Stat1a are able to inhibit Smad-driven
promoter transactivation by competing with Smad for limiting
amounts of cellular p300 (Bitzer et al, 2000; Ghosh et al, 2000;
Verrecchia et al, 2000). These mechanisms may explain, at least in
part, the antagonistic activity of tumor necrosis factor-a and
interferon-g on TGF-b-driven COL1A2 expression (Chung et al,
1996; Verrecchia et al, 2000; Ghosh et al, 2001).
Other approaches may include local overexpression of the
inhibitory Smad, Smad7, targeting of connective tissue growth
factor in situations where it is proven to be the mediator of the
TGF-b effect on ECM deposition, Several options have been
discussed in a recent review (Branton and Kopp, 1999).
CONCLUSIONS AND PERSPECTIVES
Tremendous progress has been accomplished over the past several
years in the understanding of the initial steps of TGF-b intracellular
signaling. The identi®cation of Smad proteins as direct links
between the cell surface and the nucleus has allowed for the
elucidation of critical events leading to gene activation by TGF-b.
Several hurdles remain before the TGF-b/Smad pathway can be
targeted directly in situations such as tissue ®brosis or impaired
wound healing. The cell-type speci®city of Smad3 effects, together
with the identi®cation of alternate signaling pathways for TGF-b
remain of critical importance. For example, even though ®brillar
collagens have been identi®ed as direct Smad3/4 target genes, it has
been demonstrated that Smad3-de®cient mice heal faster than their
wild-type counterparts, due to accelerated re-epithelialization and
reduced monocytic in¯ux at the site of injury. In these mice,
exogenously added TGF-b can still activate type I collagen gene
expression. These data suggest that, in vivo, Smad3 may have effects
that are inhibitory to wound healing. Also, they indicate that
disruption of the Smad3 pathway in vivo, coupled with exogenous
TGF-b signaling through intact alternate pathways, may be of
therapeutic bene®t in accelerating all aspects of impaired wound
healing.
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